Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Fig. 2

Lesion level time to response (Kaplan-Meier survival curves) for talimogene laherparepvec for injected, all uninjected, uninjected non-visceral, or visceral lesions in the phase II clinical trial of talimogene laherparepvec in patients with stage IIIC or IV melanoma. Safety analysis set consisted of patients who received at least one dose of study therapy

Back to article page